JC
BMRN icon

JBF Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

JBF Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,560
Closed -$1.02M – 90
2018
Q3 		$1.02M Hold
10,560
– – 0.15% 27
2018
Q2 		$995K Sell
10,560
-2,000
-16% -$175K 0.15% 41
2018
Q1 		$1.02M Buy
+12,560
New +$1.08M 0.16% 36

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JBF Capital's BMRN Position: Q4 2018 in Review

JBF Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 10,560 shares — an estimated $1.02M sold.

JBF Capital first reported a position in BMRN in Q1 2018 and held it in 3 quarters. The position peaked at $1.02M in Q3 2018. 473 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

  • JBF Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • JBF Capital sold 10,560 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $1.02M.
  • JBF Capital first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • JBF Capital's BioMarin Pharmaceuticals position peaked at $1.02M in Q3 2018.
  • 473 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.